{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:53:05Z","timestamp":1764240785752,"version":"3.44.0"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"30","funder":[{"name":"Scientific Research Project of Wuhan Health Commission","award":["WZ21Q11"],"award-info":[{"award-number":["WZ21Q11"]}]},{"DOI":"10.13039\/501100003819","name":"Hubei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022CFB980"],"award-info":[{"award-number":["2022CFB980"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and hepatitis B and C are the main pathogenic factors of hepatocellular carcinoma (HCC). Though\nthe current understanding of risk factors for HCC has been improved, patients with this type\nof cancer are normally diagnosed at advanced stages, posing significant challenges to effective treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This study analyzed the HCC datasets from The Cancer Genome Atlas (TCGA)\nand Gene Expression Omnibus (GEO) database (GSE14520 and GSE116174). Stromal and\nimmune cell infiltration in the tumor microenvironment (TME) was quantified by the ESTIMATE algorithm. To identify gene modules associated with cancer-associated fibroblasts\n(CAFs), weighted gene co-expression network analysis (WGCNA) was performed to develop gene co-expression networks. A CAF prognosis score (CAFPS) model was established\nbased on the prognostic CAF genes screened by univariate and multivariate Cox regression\nanalyses. To determine the role of the genes in the vital module in HCC, we conducted\nGene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Finally, the relationship between CAFPS and drug sensitivity was analyzed using Genomic\nData for Cancer Drug Sensitivity (GDSC)<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In this study, we found significant differences in immune scores, stromal scores,\nCAFs scores, and CD4\/8 T-cell scores between normal samples and samples with different\nTNM staging. In particular, the proportion of CAFs was higher than all other cells in normal\nsamples. Gene modules related to CAFs were identified by developing a gene co-expression\nnetwork using WGCNA analysis. The lightyellow and greenyellow modules showed the\nhighest correlation with CAF scores. Univariate COX analysis identified 12 genes related to\nHCC prognosis from a total of 191 genes in the two modules. The Kaplan-Meier (KM) survival analysis revealed that a high expression of these genes was associated with a lower survival chance. Based on the 12 genes obtained by univariate COX analysis, multivariate\nCOX analysis was performed to construct a risk score model for the characteristics of CAFs\n(CAFPS). The KM survival curves of patients in the high CAFPS and low CAFPS groups\nshowed that patients in the low CAFPS group had better survival.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>CAFs played a crucial role in the pathogenesis and treatment response of\nHCC. Targeting the CAFs milieu may provide therapeutic benefits, highlighting the importance of CAFS in developing a personalized treatment for HCC patients. Further studies are\nrequired to verify the current findings and explore their implications in clinical settings.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673322216240711113419","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T03:01:33Z","timestamp":1721271693000},"page":"6646-6665","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a Cancer-associated Fibroblast Signature for Evaluating Immunotherapy Response and Prognosis of Hepatocellular Carcinoma"],"prefix":"10.2174","volume":"32","author":[{"given":"Hui","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan No.1 Hospital, Wuhan, 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Wuhan No.1 Hospital, Wuhan, 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan No.1 Hospital, Wuhan, 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan No.1 Hospital, Wuhan, 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013,\nChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan No.1 Hospital, Wuhan, 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","volume":"27","author":"Ganesan P.","year":"2023","unstructured":"Ganesan P.; Kulik L.M.; Hepatocellular carcinoma. Clin Liver Dis  2023,27(1),85-102","journal-title":"Clin Liver Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5582\/bst.2022.01061","volume":"16","author":"Wen N.","year":"2022","unstructured":"Wen N.; Cai Y.; Li F.; Ye H.; Tang W.; Song P.; Cheng N.; The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends  2022,16(1),20-30","journal-title":"Biosci Trends"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"ltab026","DOI":"10.1093\/immadv\/ltab026","volume":"2","author":"Tan A.T.","year":"2022","unstructured":"Tan A.T.; Bertoletti A.; HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunother Adv  2022,2(1),ltab026","journal-title":"Immunother Adv"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"601240","DOI":"10.3389\/fonc.2020.601240","volume":"10","author":"Donisi C.","year":"2021","unstructured":"Donisi C.; Puzzoni M.; Ziranu P.; Lai E.; Mariani S.; Saba G.; Impera V.; Dubois M.; Persano M.; Migliari M.; Pretta A.; Liscia N.; Astara G.; Scartozzi M.; Immune checkpoint inhibitors in the treatment of HCC. Front Oncol  2021,10,601240","journal-title":"Front Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3748\/wjg.v20.i15.4115","volume":"20","author":"Raza A.","year":"2014","unstructured":"Raza A.; Sood G.K.; Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol  2014,20(15),4115-4127","journal-title":"World J Gastroenterol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1515\/oncologie-2023-0534","volume":"26","author":"Kurdi M.","year":"2024","unstructured":"Kurdi M.; Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression. Oncologie  2024,26(2),239-246","journal-title":"Oncologie"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"Brown Z.J.","year":"2023","unstructured":"Brown Z.J.; Tsilimigras D.I.; Ruff S.M.; Mohseni A.; Kamel I.R.; Cloyd J.M.; Pawlik T.M.; Management of hepatocellular carcinoma. JAMA Surg  2023,158(4),410-420","journal-title":"JAMA Surg"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.32604\/oncologie.2021.018869","volume":"23","author":"Zhu X.","year":"2021","unstructured":"Zhu X.; Wang Y.; Chang S.; Su Y.; He C.; Hu S.; Zhu M.; Ding Y.; Ren N.; Wang Q.; Xie J.; Zhou H.; Epigenetics of sirtuins: Relevance to hepatocellular carcinoma. Oncologie  2021,23(4),569-588","journal-title":"Oncologie"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Liu Y.","year":"2023","unstructured":"Liu Y.; Xun Z.; Ma K.; Liang S.; Li X.; Zhou S.; Sun L.; Liu Y.; Du Y.; Guo X.; Cui T.; Zhou H.; Wang J.; Yin D.; Song R.; Zhang S.; Cai W.; Meng F.; Guo H.; Zhang B.; Yang D.; Bao R.; Hu Q.; Wang J.; Ye Y.; Liu L.; Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol  2023,78(4),770-782","journal-title":"J Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"Chen C.","year":"2023","unstructured":"Chen C.; Wang Z.; Ding Y.; Qin Y.; Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol  2023,14,1133308","journal-title":"Front Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s10269-017-2712-2","volume":"19","author":"Bouattour M.","year":"2017","unstructured":"Bouattour M.; Raymond E.; Faivre S.; Hepatocellular carcinoma: New concepts, new drugs and new approaches. Oncologie  2017,19(5-6),168-176","journal-title":"Oncologie"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-019-0782-x","volume":"12","author":"Yin Z.","year":"2019","unstructured":"Yin Z.; Dong C.; Jiang K.; Xu Z.; Li R.; Guo K.; Shao S.; Wang L.; Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol  2019,12(1),101","journal-title":"J Hematol Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"15","author":"Ying F.","year":"2023","unstructured":"Ying F.; Chan M.S.M.; Lee T.K.W.; Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell Mol Gastroenterol Hepatol  2023,15(4),985-999","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-022-00406-z","volume":"10","author":"Peng H.","year":"2022","unstructured":"Peng H.; Zhu E.; Zhang Y.; Advances of cancer-associated fibroblasts in liver cancer. Biomark Res  2022,10(1),59","journal-title":"Biomark Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.7150\/thno.72853","volume":"12","author":"Giguelay A.","year":"2022","unstructured":"Giguelay A.; Turtoi E.; Khelaf L.; Tosato G.; Dadi I.; Chastel T.; Poul M.A.; Pratlong M.; Nicolescu S.; Severac D.; Adenis A.; Sgarbura-Popescu O.; Carr\u00e8re S.; Rouanet P.; Quenet F.; Ychou M.; Pourqier D.; Colombo P.E.; Turtoi A.; Colinge J.; The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases. Theranostics  2022,12(17),7624-7639","journal-title":"Theranostics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/cells9092027","volume":"9","author":"Kaps L.","year":"2020","unstructured":"Kaps L.; Schuppan D.; Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells  2020,9(9),2027","journal-title":"Cells"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"Affo S.","year":"2017","unstructured":"Affo S.; Yu L.X.; Schwabe R.F.; The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol  2017,12(1),153-186","journal-title":"Annu Rev Pathol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcmgh.2020.09.003","volume":"11","author":"Liu J.","year":"2021","unstructured":"Liu J.; Li P.; Wang L.; Li M.; Ge Z.; Noordam L.; Lieshout R.; Verstegen M.M.A.; Ma B.; Su J.; Yang Q.; Zhang R.; Zhou G.; Carrascosa L.C.; Sprengers D.; IJzermans J.N.M.; Smits R.; Kwekkeboom J.; van der Laan L.J.W.; Peppelenbosch M.P.; Pan Q.; Cao W.; Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance. Cell Mol Gastroenterol Hepatol  2021,11(2),407-431","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/ijms24043941","volume":"24","author":"Akk\u0131z H.","year":"2023","unstructured":"Akk\u0131z H.; Emerging role of cancer-associated fibroblasts in progression and treatment of hepatocellular carcinoma. Int J Mol Sci  2023,24(4),3941","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"Yoshihara K.","year":"2013","unstructured":"Yoshihara K.; Shahmoradgoli M.; Mart\u00ednez E.; Vegesna R.; Kim H.; Torres-Garcia W.; Trevi\u00f1o V.; Shen H.; Laird P.W.; Levine D.A.; Carter S.L.; Getz G.; Stemke-Hale K.; Mills G.B.; Verhaak R.G.W.; Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun  2013,4(1),2612","journal-title":"Nat Commun"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"Langfelder P.","year":"2008","unstructured":"Langfelder P.; Horvath S.; WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics  2008,9(1),559","journal-title":"BMC Bioinformatics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"Yu G.","year":"2012","unstructured":"Yu G.; Wang L.G.; Han Y.; He Q.Y.; ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS  2012,16(5),284-287","journal-title":"OMICS"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.32604\/chd.2023.047689","volume":"18","author":"Zulibiya A.","year":"2023","unstructured":"Zulibiya A.; Wen J.; Yu H.; Chen X.; Xu L.; Ma X.; Zhang B.; Single-cell RNA sequencing reveals potential for endothelial-to-mesenchymal transition in tetralogy of fallot. Congenit Heart Dis  2023,18(6),611-625","journal-title":"Congenit Heart Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"Geeleher P.","year":"2014","unstructured":"Geeleher P.; Cox N.; Huang R.S.; pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One  2014,9(9),e107468","journal-title":"PLoS One"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"Kobayashi H.","year":"2019","unstructured":"Kobayashi H.; Enomoto A.; Woods S.L.; Burt A.D.; Takahashi M.; Worthley D.L.; Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol  2019,16(5),282-295","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13059-018-1604-0","volume":"20","author":"Qin X.","year":"2019","unstructured":"Qin X.; Guo H.; Wang X.; Zhu X.; Yan M.; Wang X.; Xu Q.; Shi J.; Lu E.; Chen W.; Zhang J.; Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol  2019,20(1),12","journal-title":"Genome Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","volume":"9","author":"Cheng Y.","year":"2018","unstructured":"Cheng Y.; Li H.; Deng Y.; Tai Y.; Zeng K.; Zhang Y.; Liu W.; Zhang Q.; Yang Y.; Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis  2018,9(4),422","journal-title":"Cell Death Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"Song M.","year":"2021","unstructured":"Song M.; He J.; Pan Q.Z.; Yang J.; Zhao J.; Zhang Y.J.; Huang Y.; Tang Y.; Wang Q.; He J.; Gu J.; Li Y.; Chen S.; Zeng J.; Zhou Z.Q.; Yang C.; Han Y.; Chen H.; Xiang T.; Weng D.S.; Xia J.C.; Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology  2021,73(5),1717-1735","journal-title":"Hepatology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ejso.2020.08.002","volume":"47","author":"Yugawa K.","year":"2021","unstructured":"Yugawa K.; Yoshizumi T.; Mano Y.; Itoh S.; Harada N.; Ikegami T.; Kohashi K.; Oda Y.; Mori M.; Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol  2021,47(2),384-393","journal-title":"Eur J Surg Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/ijo.2021.5239","volume":"59","author":"Chen S.","year":"2021","unstructured":"Chen S.; Morine Y.; Tokuda K.; Yamada S.; Saito Y.; Nishi M.; Ikemoto T.; Shimada M.; Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway. Int J Oncol  2021,59(2),59","journal-title":"Int J Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"Feng B.","year":"2022","unstructured":"Feng B.; Wu J.; Shen B.; Jiang F.; Feng J.; Cancer-associated fibroblasts and resistance to anticancer therapies: Status, mechanisms, and countermeasures. Cancer Cell Int  2022,22(1),166","journal-title":"Cancer Cell Int"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"Mao X.","year":"2021","unstructured":"Mao X.; Xu J.; Wang W.; Liang C.; Hua J.; Liu J.; Zhang B.; Meng Q.; Yu X.; Shi S.; Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer  2021,20(1),131","journal-title":"Mol Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"Pei L.","year":"2023","unstructured":"Pei L.; Liu Y.; Liu L.; Gao S.; Gao X.; Feng Y.; Sun Z.; Zhang Y.; Wang C.; Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer  2023,22(1),29","journal-title":"Mol Cancer"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1038\/s41467-022-33991-6","volume":"13","author":"Kim D.K.","year":"2022","unstructured":"Kim D.K.; Jeong J.; Lee D.S.; Hyeon D.Y.; Park G.W.; Jeon S.; Lee K.B.; Jang J.Y.; Hwang D.; Kim H.M.; Jung K.; PD-L1-directed PlGF\/VEGF blockade synergizes with chemotherapy by targeting CD141 cancer-associated fibroblasts in pancreatic cancer. Nat Commun  2022,13(1),6292","journal-title":"Nat Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"46253","DOI":"10.18632\/oncotarget.10086","volume":"7","author":"Tang Z.","year":"2016","unstructured":"Tang Z.; Shen Q.; Xie H.; Zhou X.; Li J.; Feng J.; Liu H.; Wang W.; Zhang S.; Ni S.; Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget  2016,7(29),46253-46262","journal-title":"Oncotarget"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcb.24649","volume":"115","author":"Ribeiro N.","year":"2014","unstructured":"Ribeiro N.; Sousa S.R.; Brekken R.A.; Monteiro F.J.; Role of SPARC in bone remodeling and cancer-related bone metastasis. J Cell Biochem  2014,115(1),17-26","journal-title":"J Cell Biochem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13578-023-00993-w","volume":"13","author":"Wu Z.","year":"2023","unstructured":"Wu Z.; Ge L.; Ma L.; Lu M.; Song Y.; Deng S.; Duan P.; Du T.; Wu Y.; Zhang Z.; Zhang S.; TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1. Cell Biosci  2023,13(1),39","journal-title":"Cell Biosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.3390\/cancers15184519","volume":"15","author":"Ling W.","year":"2023","unstructured":"Ling W.; Johnson S.K.; Mehdi S.J.; Alapat D.V.; Bauer M.; Zangari M.; Schinke C.; Thanendrarajan S.; van Rhee F.; Yaccoby S.; EDNRA-expressing mesenchymal cells are expanded in myeloma interstitial bone marrow and associated with disease progression. Cancers (Basel)  2023,15(18),4519","journal-title":"Cancers (Basel)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fimmu.2020.02026","volume":"11","author":"Dou D.","year":"2020","unstructured":"Dou D.; Ren X.; Han M.; Xu X.; Ge X.; Gu Y.; Wang X.; Cancer-associated fibroblasts-derived exosomes suppress immune cell function in breast cancer via the miR-92\/PD-L1 pathway. Front Immunol  2020,11,2026","journal-title":"Front Immunol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673322216240711113419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231942\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673322216240711113419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:42:20Z","timestamp":1758775340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231942\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673322216240711113419","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}